Nav: Home

New Phase 1 clinical trial to test Durvalumab in pediatric patients

August 17, 2016

In an innovative, first-in-pediatrics study, available only at Children's Hospital Los Angeles (CHLA), researchers will be enrolling children between 1 and 18 years of age who have certain types of relapsed or treatment-resistant cancer.

The aim of this investigator-initiated Phase 1 trial is to test the safety, tolerability and metabolism of the drug Durvalumab in pediatric patients with solid tumors, lymphoma and central nervous system tumors.

Durvalumab, which is also being investigated in several types of adult cancer, is what is known as a checkpoint inhibitor. A "checkpoint" is a molecule that is activated or inactivated to allow the body's immune system to attack foreign cells while leaving normal cells alone. Cancer cells often find ways to evade these checkpoints to avoid being attacked by the immune system.

Drugs like Durvalumab can target such checkpoints and boost the immune response against cancer cells.

PD-1 is a checkpoint protein found on T cells which normally signals the T cell to turn off its immune response. When PD-1 attached to another protein - PD-L1 - that is found on cancer cells, it allows the cancer to evade immune attack.

"By shutting off the signal by inhibiting PDL-1, Durvalumab in essence allows the body's own T cells to recognize the cancerous cells as 'foreign' and attack them," said Leo Mascarenhas, MD, MS, deputy director and head of oncology at CHLA's Children's Center for Cancer and Blood Diseases. Mascarenhas and Josephine HaDuong, MD, co-lead investigators of the study, seek to enroll between 18 and 24 young patients with cancer.

"This is an example of how Children's Hospital Los Angeles offers the newest, cutting-edge treatments to our patients," says Mascarenhas.
This research is being conducted with support from AstraZeneca Pharmaceuticals LP.

The Children's Center for Cancer and Blood Diseases (CCCBD) at Children's Hospital Los Angeles has been ranked by U.S. News and World Report among the top 10 pediatric cancer centers in the country since these rankings began in 2008. It has one of the largest programs of clinical trials for children with cancer and blood disorders in the U.S., enrolling nearly 1,400 children in more than 140 different trials each year. The CCCBD is part of the 20-member Pediatric Phase 1 Pilot Consortium, funded by the National Cancer Institute to improve therapy outcomes for children with cancer.

About Children's Hospital Los Angeles

Children's Hospital Los Angeles has been named the best children's hospital in California and among the top 10 in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children's Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children's Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California. For more information, visit Follow us on Twitter, Facebook, YouTube and LinkedIn, or visit our blog at

Children's Hospital Los Angeles

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
More Cancer News and Cancer Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...